- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07621419
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin (SEMA-REAL ARG)
New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study
The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events.
Participants will receive semaglutide as prescribed by their treating physician as part of routine clinical care. Follow-up assessments will be performed at 3, 6, and 12 months to collect clinical, laboratory, safety, treatment satisfaction, and adherence data. Treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and adherence will be assessed using the Simplified Medication Adherence Questionnaire (SMAQ).
Aperçu de l'étude
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Martín L Gil Folgar, MD
- Numéro de téléphone: +5411 1520497361
- E-mail: martin.gilfolgar@hospitalitaliano.org.ar
Sauvegarde des contacts de l'étude
- Nom: Natalia Nachón, MD
- Numéro de téléphone: +54 9 11 155876-3407
- E-mail: dra.nachon@gmail.com
Lieux d'étude
-
-
Buenos Aires
-
Buenos Aires, Buenos Aires, Argentine, 1199
- Recrutement
- Hospital Italiano de Buenos Aires
-
Contact:
- Martín L Gil Folgar, MD
- Numéro de téléphone: +5411 1520497361
- E-mail: martin.gilfolgar@hospitalitaliano.org.ar
-
Buenos Aires, Buenos Aires, Argentine, 1427
- Recrutement
- Hospital General de Agudos Dr Enrique Tornú
-
Contact:
- María N Nachón, MD
- Numéro de téléphone: +54 9 11 155876-3407
- E-mail: dra.nachon@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years.
- Clinical diagnosis of type 2 diabetes mellitus.
- Baseline glycated hemoglobin (HbA1c) >7% and ≤12%.
- Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment.
Exclusion Criteria:
- Pregnancy or lactation at the time of enrollment.
- History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists.
- Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors).
- Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Patients with Type 2 Diabetes Treated with Semaglutide (Oral or Subcutaneous)
This cohort includes adults aged 18 years or older with type 2 diabetes mellitus who initiate treatment with oral or subcutaneous semaglutide as prescribed by their treating physician in routine clinical practice.
The study is observational and does not assign treatment.
Dose, formulation, and route of administration are determined by the treating physician according to standard care.
|
Participants will receive semaglutide as part of their usual medical care for type 2 diabetes mellitus.
The intervention of interest includes both oral and subcutaneous formulations of semaglutide, prescribed and dosed at the discretion of the treating physician according to routine clinical practice.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in glycated hemoglobin (HbA1c) levels from baseline to 3, 6, and 12 months of follow-up.
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Mean change in HbA1c (%) compared with baseline among adult patients with type 2 diabetes treated with oral or subcutaneous semaglutide in real-world clinical practice.
|
Baseline, 3 months, 6 months, and 12 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Body Weight
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Mean change in body weight (kg) compared with baseline.
|
Baseline, 3 months, 6 months, and 12 months.
|
|
Change in Waist Circumference
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Mean change in waist circumference (cm) compared with baseline.
|
Baseline, 3 months, 6 months, and 12 months.
|
|
Change in Hand-Grip Strength
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Mean change in grip strength (kg) measured with a hand dynamometer.
|
Baseline, 3 months, 6 months, and 12 months.
|
|
Treatment Satisfaction Assessed With the Diabetes Treatment Satisfaction Questionnaire
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Change from baseline in treatment satisfaction assessed using the Diabetes Treatment Satisfaction Questionnaire.
The total treatment satisfaction score ranges from 0 to 36, with higher scores indicating greater treatment satisfaction.
|
Baseline, 3 months, 6 months, and 12 months.
|
|
Treatment Adherence Assessed With the Simplified Medication Adherence Questionnaire
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Proportion of participants classified as adherent according to the Simplified Medication Adherence Questionnaire.
Participants will be classified as adherent or non-adherent according to the questionnaire scoring rules.
|
Baseline, 3 months, 6 months, and 12 months.
|
|
Proportion of Patients Switching Administration Route
Délai: Up to 12 months.
|
Percentage of participants switching between oral and subcutaneous semaglutide, including direction and reason for change.
|
Up to 12 months.
|
|
Reasons for Treatment Discontinuation
Délai: Up to 12 months.
|
Frequency and type of reasons for discontinuation (adverse events, inefficacy, patient decision, etc.).
|
Up to 12 months.
|
|
Adverse Events
Délai: Up to 12 months.
|
Incidence and severity of adverse events, categorized by system organ class and relationship to semaglutide.
|
Up to 12 months.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Semaglutide Dose Over Time
Délai: Baseline, 3 months, 6 months, and 12 months.
|
Evaluation of dose adjustments (increases or reductions) across follow-up visits.
|
Baseline, 3 months, 6 months, and 12 months.
|
|
Subgroup Analysis by Administration Route
Délai: Up to 12 months.
|
Comparison of glycemic and anthropometric outcomes between patients receiving oral vs. subcutaneous semaglutide.
|
Up to 12 months.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: María Natalia Nachón, MD, Hospital General de Agudos Dr Enrique Tornú
- Directeur d'études: Iván A Huespe, MD, Hospital Italiano de Buenos Aires
- Chaise d'étude: Matías Mirofsky, MD, Hospital Leónidas Lucero, Bahía Blanca
Publications et liens utiles
Publications générales
- Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, Kindelan JM, Carmona A, Juega J, Ocampo A; GEEMA Study Group. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002 Mar 8;16(4):605-13. doi: 10.1097/00002030-200203080-00012.
- Rojas-Roque C, Hernandez-Vasquez A, Azanedo D, Bendezu-Quispe G. Socioeconomic Inequalities in the Prevalence of Diabetes in Argentina: A Repeated Cross-Sectional Study in Urban Women and Men. Int J Environ Res Public Health. 2022 Jul 22;19(15):8888. doi: 10.3390/ijerph19158888.
- Burgos MA, Morales Mendez EJ, Russo MP, Martingano I, Lopez Gutierrez MP, Maccio AM, Segalini A, Plazzotta F, Otero C, Orrego N, Grande Ratti MF. Utilizing Secondary Data from Electronic Health Records for Automated Frailty Detection in Older Adults with Diabetes. Stud Health Technol Inform. 2025 Aug 7;329:179-183. doi: 10.3233/SHTI250825.
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S181-S206. doi: 10.2337/dc25-S009.
- Saravanan P, Bell H, Braae UC, Collins E, Deinega A, Dhatariya K, Machell A, Trent A, Strzelecka A. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes. Adv Ther. 2024 Nov;41(11):4266-4281. doi: 10.1007/s12325-024-02973-z. Epub 2024 Sep 24.
- Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzik M; PIONEER 1 Investigators. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019 Sep;42(9):1724-1732. doi: 10.2337/dc19-0749. Epub 2019 Jun 11.
- Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Troubles nutritionnels
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- En surpoids
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- Obésité
- Diabète sucré, Type 2
- Diabète sucré
- sémaglutide
Autres numéros d'identification d'étude
- 15820
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .